Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $351000.0.

  • Karyopharm Therapeutics' Other Non-Current Assets fell 7368.82% to $351000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $351000.0, marking a year-over-year decrease of 7368.82%. This contributed to the annual value of $351000.0 for FY2025, which is 7368.82% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Other Non-Current Assets of $351000.0 as of Q4 2025, which was down 7368.82% from $1.3 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Other Non-Current Assets' 5-year high stood at $1.3 million during Q4 2024, with a 5-year trough of $301000.0 in Q4 2023.
  • Its 5-year average for Other Non-Current Assets is $673150.0, with a median of $633500.0 in 2022.
  • In the last 5 years, Karyopharm Therapeutics' Other Non-Current Assets soared by 34318.94% in 2024 and then tumbled by 7368.82% in 2025.
  • Karyopharm Therapeutics' Other Non-Current Assets (Quarter) stood at $637000.0 in 2021, then fell by 0.63% to $633000.0 in 2022, then crashed by 52.45% to $301000.0 in 2023, then surged by 343.19% to $1.3 million in 2024, then plummeted by 73.69% to $351000.0 in 2025.
  • Its last three reported values are $351000.0 in Q4 2025, $1.3 million for Q3 2025, and $1.3 million during Q2 2025.